ABCELLERA BIOLOGICS (F:8QQ) — Stock Price
ABCELLERA BIOLOGICS (F:8QQ) is currently trading at €5.63 EUR, up 8.27% today. Over the past 52 weeks, shares have ranged between €2.49 and €7.65. This page tracks ABCELLERA BIOLOGICS's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 8QQ market cap.
ABCELLERA BIOLOGICS (8QQ) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ABCELLERA BIOLOGICS's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
ABCELLERA BIOLOGICS Income Statement — Revenue, Profit & Earnings by Year
ABCELLERA BIOLOGICS's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €75.13 Million | €28.83 Million | €38.02 Million | €485.42 Million | €375.20 Million |
| Cost of Revenue | — | €0.00 | €0.00 | €66.44 Million | €45.52 Million |
| Gross Profit | — | €28.83 Million | €38.02 Million | €418.99 Million | €329.69 Million |
| Research & Development | €186.83 Million | €167.26 Million | €175.66 Million | €107.88 Million | €62.06 Million |
| SG&A | €83.23 Million | €85.49 Million | €75.18 Million | €66.75 Million | €48.76 Million |
| Total Operating Expenses | €278.34 Million | €329.98 Million | €261.08 Million | €258.36 Million | €153.30 Million |
| Operating Income | €-203.21 Million | €-301.15 Million | €-223.05 Million | €227.06 Million | €221.90 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | — | — | — | €4.04 Million | €5.22 Million |
| Income Before Tax | €-177.59 Million | €-200.40 Million | €-174.03 Million | €239.10 Million | €219.15 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-146.41 Million | €-162.86 Million | €-146.40 Million | €158.52 Million | €153.46 Million |
ABCELLERA BIOLOGICS Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ABCELLERA BIOLOGICS's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €1.36 Billion | €1.36 Billion | €1.49 Billion | €1.54 Billion | €1.32 Billion |
| Total Current Assets | €728.23 Million | €751.37 Million | €871.99 Million | €1.03 Billion | €929.80 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €405.31 Million | €469.29 Million | €627.26 Million | €499.95 Million | €246.84 Million |
| Net Receivables | €58.29 Million | €33.62 Million | €30.59 Million | €38.59 Million | €160.58 Million |
| Inventory | €6.34 Million | €0.00 | €1.11 Million | €1.53 Million | €1.67 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €47.81 Million | €47.81 Million | €47.81 Million | €47.81 Million | €47.81 Million |
| Total Liabilities | €390.05 Million | €304.47 Million | €335.78 Million | €307.63 Million | €292.84 Million |
| Total Current Liabilities | €64.31 Million | €76.61 Million | €119.01 Million | €118.32 Million | €120.68 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €966.90 Million | €1.06 Billion | €1.15 Billion | €1.23 Billion | €1.03 Billion |
| Retained Earnings | €-29.48 Million | €116.93 Million | €279.79 Million | €426.19 Million | €267.67 Million |
ABCELLERA BIOLOGICS Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ABCELLERA BIOLOGICS generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-131.29 Million | €-108.56 Million | €-43.88 Million | €277.36 Million | €244.58 Million |
| Capital Expenditures | €42.77 Million | €78.40 Million | €77.51 Million | €72.66 Million | €58.45 Million |
| Free Cash Flow | €-174.07 Million | €-186.95 Million | €-121.38 Million | €204.70 Million | €186.13 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €14.08 Million | €12.77 Million | €10.36 Million | €-1.63 Million | €-3.89 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €55.79 Million | €67.58 Million | €64.18 Million | €49.48 Million | €30.65 Million |
| Depreciation | €28.82 Million | €97.00 Million | €30.89 Million | €33.10 Million | €17.25 Million |
| Change in Cash | €-28.37 Million | €23.00 Million | €-254.04 Million | €-86.49 Million | €-92.97 Million |
ABCELLERA BIOLOGICS Earnings History — EPS Actual vs. Analyst Estimates
Track ABCELLERA BIOLOGICS's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 11, 2026 | — | -0.20 | — |
| Feb 24, 2026 | — | -0.18 | — |
| Nov 06, 2025 | — | -0.16 | — |
| May 05, 2025 | — | — | — |
| Feb 18, 2025 | — | — | — |
| Nov 04, 2024 | — | — | — |
| Jun 30, 2021 | -0.01 | 0.08 | -112.50% |
| Mar 31, 2021 | 0.37 | 0.38 | -2.63% |